Prosecution Insights
Last updated: October 01, 2026
Application No. 18/549,711

HAIR COLOURING COMPOSITION COMPRISING AT LEAST ONE (POLY)CARBODIIMIDE COMPOUND AND AT LEAST ONE COMPOUND COMPRISING AT LEAST ONE HYDROXYL FUNCTION

Final Rejection §DP
Filed
Sep 08, 2023
Priority
Mar 10, 2021 — FR 2102357 +1 more
Examiner
ABBAS, ABDULRAHMAN MUSTAFA
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L'Oréal
OA Round
2 (Final)
52%
Grant Probability
Moderate
3-4
OA Rounds
2m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
33 granted / 63 resolved
-7.6% vs TC avg
Strong +35% interview lift
Without
With
+34.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
44 currently pending
Career history
113
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
51.3%
+11.3% vs TC avg
§102
8.0%
-32.0% vs TC avg
§112
17.0%
-23.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 63 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims included in prosecution are claims 1 and 8-23. Previous Rejections Applicants' arguments, filed 7/21/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 1. Claims 1 and 8-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-26 of copending Application No. 18/549,858 in view of Elsen-Wahrer et al. (US 2017/0189314, Jul. 6, 2017) (hereinafter Elsen-Wahrer). The pending claims differ from the copending claims insofar as reciting at least one compound containing at least one hydroxyl function. However, Elsen-Wahrer discloses treatment compositions and processes related thereto for treating keratinous substrates, in particular for hair-care comprising a polycarbodiimide and carboxysilicone polymer (Abstract). The composition may include other suitable ingredients for hair treatment or hair repair. For example, known solvents and/or additives may be utilized in addition to the polycarbodiimide and carboxysilicone polymers to provide additional benefits to the composition (¶ [0047]). Suitable solvents for treatment of keratinous fibers. include organic solvents (¶ [0115]). Suitable organic solvents include ethanol (i.e., compound containing at least one hydroxyl function) (¶ [0117]). Accordingly, it would have been obvious to one of ordinary skill in the art to have incorporated ethanol into the pending claims since it is a known and effective additive for use in hair care compositions comprising polycarbodiimide as taught by Elsen-Wahrer. This is a provisional nonstatutory double patenting rejection. 2. Claims 1 and 8-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 25, 28-32, 34, 35, 38-40, and 42-45 of copending Application No. 17/778,353 in view of Elsen-Wahrer et al. (US 2017/0189314, Jul. 6, 2017) (hereinafter Elsen-Wahrer). The pending claims differ from the copending claims insofar as reciting at least one compound containing at least one hydroxyl function and at least one associative polymer. However, Elsen-Wahrer discloses treatment compositions and processes related thereto for treating keratinous substrates, in particular for hair-care comprising a polycarbodiimide and carboxysilicone polymer (Abstract). The composition may include other suitable ingredients for hair treatment or hair repair. For example, known solvents and/or additives may be utilized in addition to the polycarbodiimide and carboxysilicone polymers to provide additional benefits to the composition (¶ [0047]). Suitable solvents for treatment of keratinous fibers. include organic solvents (¶ [0115]). Suitable organic solvents include ethanol (i.e., compound containing at least one hydroxyl function) (¶ [0117]). Suitable additives include polymeric rheology modifiers (¶ [0130]). Suitable polymeric rheology modifiers include anionic polymers, for example associative polymers (¶ [0189]). Accordingly, it would have been obvious to one of ordinary skill in the art to have incorporated an associative polymer and ethanol into the pending claims since they are known and effective solvents/additives for use in hair care compositions comprising polycarbodiimide as taught by Elsen-Wahrer. This is a provisional nonstatutory double patenting rejection. 3. Claims 1 and 8-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 8-22 of copending Application No. 18/549,692 in view of Elsen-Wahrer et al. (US 2017/0189314, Jul. 6, 2017) (hereinafter Elsen-Wahrer). The pending claims differ from the copending claims insofar as reciting at least one compound containing at least one hydroxyl function. However, Elsen-Wahrer discloses treatment compositions and processes related thereto for treating keratinous substrates, in particular for hair-care comprising a polycarbodiimide and carboxysilicone polymer (Abstract). The composition may include other suitable ingredients for hair treatment or hair repair. For example, known solvents and/or additives may be utilized in addition to the polycarbodiimide and carboxysilicone polymers to provide additional benefits to the composition (¶ [0047]). Suitable solvents for treatment of keratinous fibers. include organic solvents (¶ [0115]). Suitable organic solvents include ethanol (i.e., compound containing at least one hydroxyl function) (¶ [0117]). Accordingly, it would have been obvious to one of ordinary skill in the art to have incorporated ethanol into the pending claims since it is a known and effective additive for use in hair care compositions comprising polycarbodiimide as taught by Elsen-Wahrer. This is a provisional nonstatutory double patenting rejection. Response to Arguments Regarding the rejection of claims 1 and 8-23 on the grounds of non-statutory double patenting, Applicants‘ arguments and the amendment have been fully considered and deemed unpersuasive for the reasons that follow. Applicants have not submitted arguments or documentation (i.e. terminal disclaimer) in response to the double patenting rejection(s). Applicant requested that the double patenting rejection(s) recited above be held in abeyance until otherwise allowable subject matter is identified. Therefore, the previous rejection of non-statutory double patenting is maintained. Conclusion Claims 1 and 8-23 are rejected. Claims 2-7 and 24-28 are withdrawn. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Abdulrahman Abbas whose telephone number is (571)270-0878. The examiner can normally be reached M-F: 8:30 - 5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.A./Examiner, Art Unit 1612 /SAHANA S KAUP/Supervisory Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Sep 08, 2023
Application Filed
Mar 05, 2026
Non-Final Rejection (signed) — §DP
Apr 23, 2026
Non-Final Rejection mailed — §DP
Jul 21, 2026
Response Filed
Aug 11, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12653755
ESKETAMINE FORMULATIONS AND METHODS FOR PREPARATION AND STORAGE
4y 0m to grant Granted Jun 16, 2026
Patent 12648915
SYNERGISTIC ANTI-VIRAL PHARMACEUTICAL COMPOSITION CONTAINING TARGETING NANOPARTICLES
3y 6m to grant Granted Jun 09, 2026
Patent 12599590
VETERINARY FORMULATIONS COMPRISING RAPAMYCIN AND METHODS OF USING THE SAME FOR TREATING ANIMAL DISEASE
3y 11m to grant Granted Apr 14, 2026
Patent 12582606
TABLET AND METHOD FOR PRODUCING TABLET
4y 5m to grant Granted Mar 24, 2026
Patent 12582121
SYNERGISTIC FUNGICIDAL COMPOSITION
4y 3m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
52%
Grant Probability
87%
With Interview (+34.8%)
3y 3m (~2m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 63 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month